Stockscreener 앱 받기
0.6425
1.83%
-0.0121
Atossa Therapeutics Inc 주식(ATOS)의 최신 뉴스
Atossa Genetics Inc. (NASDAQ:ATOS) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Atossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025 - Nasdaq
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Big Picture: Is Atossa Therapeutics Inc part of any ETF2025 Fundamental Recap & Reliable Price Breakout Signals - baoquankhu1.vn
Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy - Sahm
Atossa Therapeutics (ATOS) Gains as FDA Grants Orphan Drug Statu - GuruFocus
ATOS Receives FDA Orphan Drug Designation for Duchenne Treatment - GuruFocus
Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z) - GuruFocus
Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen in Duchenne Muscular Dystrophy - Intellectia AI
Experimental DMD treatment from Atossa earns rare FDA orphan status - Stock Titan
Atossa Therapeutics (ATOS) Receives Orphan Drug Designation, Shares Rise 10% - Intellectia AI
Atossa Therapeutics (ATOS) Receives FDA Orphan Drug Designation, Shares Rise 13% - Intellectia AI
Why Did ATOS Stock Jump 10% In Pre-Market Today? - Asianet Newsable
FDA Grants Orphan Drug Status to Atossa Therapeutics' (ATOS) Z-E - GuruFocus
What Wall Street predicts for Atossa Therapeutics Inc stock priceAnalyst Upgrade & AI Forecast Swing Trade Picks - Bộ Nội Vụ
Atossa Therapeutics targets breast cancer care breakthroughs - Traders Union
Will Atossa Therapeutics Inc. (YAG2) stock beat revenue estimatesWalking Comfort Picks & HOKA buying tips before checkout - ulpravda.ru
Atossa Genetics (NASDAQ:ATOS) Shares Cross Below 200 Day Moving Average – Here’s Why - Defense World
Is Atossa Therapeutics Inc. stock in correction or buying zoneJuly 2025 Outlook & Community Verified Watchlist Alerts - Улправда
Will Atossa Therapeutics Inc. stock benefit from AI adoptionQuarterly Earnings Summary & Fast Entry Momentum Trade Alerts - Улправда
Will Atossa Therapeutics Inc. stock outperform growth indexesWeekly Stock Analysis & Verified Momentum Watchlists - Улправда
What margin trends mean for Atossa Therapeutics Inc. stockPortfolio Gains Summary & Safe Swing Trade Setups - Улправда
Is Atossa Therapeutics Inc. (YAG2) stock supported by strong fundamentalsMarket Sentiment Report & Real-Time Volume Spike Alerts - Улправда
Bearish Setup: Will Atossa Therapeutics Inc. stock maintain growth storyJuly 2025 Decliners & High Accuracy Investment Entry Signals - Улправда
FDA clears Atossa Therapeutics to begin (Z)-endoxifen study By Investing.com - Investing.com India
Atossa Therapeutics Receives FDA "Study May Proceed" Letter for - GuruFocus
Atossa Wins FDA Clearance to Advance (Z)-Endoxifen Trial - TipRanks
FDA clears Atossa Therapeutics to begin (Z)-endoxifen study - Investing.com
Atossa Therapeutics Receives FDA Approval for Metastatic Breast Cancer Study - TradingView — Track All Markets
Atossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer – Company AnnouncementFT.com - Financial Times
Reviewing Atossa Genetics (NASDAQ:ATOS) and Autonomix Medical (NASDAQ:AMIX) - Defense World
Seattle InnoDiagrid emerges from stealth I Atossa troubles - The Business Journals
Atossa Genetics Inc. (NASDAQ:ATOS) Sees Large Increase in Short Interest - Defense World
Atossa Genetics Inc. (NASDAQ:ATOS) Receives Consensus Recommendation of “Hold” from Analysts - Defense World
Atossa Genetics (NASDAQ:ATOS) Share Price Passes Below 200 Day Moving Average – Should You Sell? - Defense World
Atossa Genetics (NASDAQ:ATOS) Share Price Passes Below 200 Day Moving AverageShould You Sell? - MarketBeat
NioCorp and Atossa Therapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - norwichbulletin.com
Atossa Genetics (NASDAQ:ATOS) & IDEXX Laboratories (NASDAQ:IDXX) Head-To-Head Survey - Defense World
Will Atossa Therapeutics Inc. stock outperform international peersChart Signals & Community Consensus Trade Alerts - Улправда
Earnings Report: Is Atossa Therapeutics Inc. stock a buy before product launchesTake Profit & Smart Money Movement Tracker - Улправда
Atossa Therapeutics Earnings Notes - Trefis
Will Atossa Therapeutics Inc. stock maintain growth storyBond Market & Free AI Powered Buy and Sell Recommendations - DonanımHaber
Will Atossa Therapeutics Inc. stock maintain momentum in 2025Quarterly Earnings Report & Technical Pattern Based Signals - Улправда
Atossa Therapeutics Wins 2025 Clinical Trials Arena Research and Development Excellence Award in Precision Endocrine Therapy Category - BioSpace
Atossa Therapeutics Wins R&D Excellence Award for Precision Endocrine Therapy Innovation - Clinical Trials Arena
3.31%
2.05%
자본화:
|
볼륨(24시간):